Accès ouvert

Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study

Article scientifique 2023 Anglais

Résumé

BACKGROUND: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). MATERIALS/METHODS: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018. RESULTS: Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3-5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34). CONCLUSIONS: Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci.

Citer ce document

Sıpahı, O., Akyol, D., Örmen, B., Şentürk, G., Mermer, S., Önal, U., Amer, F., Saed, M., Özdemir, K., Tigen, E., Öztoprak, N., ALTIN, Ü., Kurtaran, B., Popescu, C., Sakci, M., Suntur, B., Gautam, V., Sharma, M., Kaya, Ş., Akçıl, E., Kaya, S., Turunç, T., Ergen, P., Kandemir, Ö., Cesur, S., Bardak-Özcem, S., Özgiray, E., Yurtseven, T., Erdem, H., Sipahi, H., Arda, B., Pullukçu, H., Tasbakan, M., Yamazhan, T., Aydemir, Ş., Ulusoy, S. (2023). Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study. https://doi.org/10.1186/s12879-023-08596-z

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Auteur(s)

Oğuz Reşat Sıpahı Deniz Akyol Bahar Örmen Gönül Çiçek Şentürk Sinan Mermer Uğur Önal Fatma Amer Maysaa Abdallah Saed Kevser Özdemir Elif Tükenmez Tigen Nefise Öztoprak Ümmügülsüm ALTIN Behice Kurtaran Corneliu Petru Popescu Mustafa Sakci Bedia Mutay Suntur Vikas Gautam Megha Sharma Şafak Kaya Eren Fatma Akçıl Selçuk Kaya Tuba Turunç Pınar Ergen Özlem Kandemir Salih Cesur Selin Bardak-Özcem Erkin Özgiray Taşkın Yurtseven Hüseyin Aytaç Erdem Hilal Sipahi Bilgin Arda Hüsnü Pullukçu Meltem Isikgoz Tasbakan Tansu Yamazhan Şöhret Aydemir Sercan Ulusoy

Statistiques

Consultations : 1

Téléchargements : 0